Mechanistic registry to study whether infection with corona virus disease 2019 (COVID-19) alters atherosclerotic plaque progression
Active Project Grant Awarded Last action
- Award ID
- R01HL159433
- Recipient
-
Icahn School Of Medicine At Mount Sinai UEI C8H9CNG1VBD9
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $9,939,877
Award facts
- Assistance listing
- 93.837 Cardiovascular Diseases Research
- Completion date 89% complete
- Originally
- Place of performance
- New York, USA
Award details come from USAspending.gov.
Description
- Abstract
- The primary objective of the corona virus disease 2019 (COVID-19) (COVID-CT) registry is to determine if infection with the severe acute respiratory syndrome coronavirus-2 (SARS-COV-2), the virus which causes COVID-19, results in marked progression of coronary atherosclerotic plaque in patients with previously defined anatomic coronary artery disease (CAD). COVID-19 induces a pro-inflammatory cytokine release and pro- thrombotic processes that we hypothesize will accelerate atherosclerotic plaque progression. Coronary computed tomographic angiography (CCTA) is a robust noninvasive method uniquely capable of measuring angiographic stenosis and quantifying and characterizing atherosclerotic plaque. Our group has extensive experience in large multicenter trials and registries using CCTA to identify key atherosclerotic plaque features associated with progression and major CAD events. Moreover, we propose use of a novel CT marker of coronary artery inflammation - the perivascular FAT attenuation index (FAI) - a marker highly predictive of acute CAD events and to assess serial changes in coronary inflammation. COVID-19 is rapidly becoming a leading cause of death with substantial evidence that pre-existing CAD increases risk of serious illness and mortality from COVID-19. By enrolling patients with high risk, atherosclerotic plaque, findings from the COVID-CT registry will inform this link between the inflammatory response sustained during COVID-19 to accelerated atherosclerotic plaque progression. If our hypotheses are confirmed, then clinicians and patients will have clear information that viral infections, such as SARS-COV-2, alter the inflammatory milieu and accelerate progression of atherosclerosis. Importantly, a connection between COVID- 19 and CAD will broadly impact preventive risk assessment for the ~7 million patients infected with SARS-COV- 2 and millions more yet to be tested in the united states. To date, evidence is lacking as to whether the COVID-19 results in marked atherosclerotic plaque progression among racially and ethnically diverse patients with CCTA-defined CAD who reside across a socioeconomically- diverse, urban setting. The present proposal constitutes a comprehensive approach assessing the clinical importance of atherosclerotic plaque progression following COVID-19. Currently, the implications of epicardial coronary injury following SARS-COV-2 infection is unknown. Yet, the inflammatory pathway of atherosclerotic plaque progression is well studied and, as such, our hypotheses are supported by this knowledge base. The proposed COVID-19 registry is poised to provide an improved mechanistic understanding of the role of viral infection on alterations in atherosclerotic plaque.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $602,559 | |
| Amendment | $1,486,653 | |
| Amendment | $1,486,653 | |
| Amendment | -$1,618,562 | |
| Amendment | $1,618,562 | |
| Amendment | -$1,618,562 | |
| Amendment | $1,618,562 | |
| Amendment | -$1,618,562 | |
| Amendment | $1,618,562 | |
| Amendment | $1,618,562 | |
| Amendment | $1,618,562 | |
| Amendment | $1,618,562 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $1,506,292 | |
| Amendment | -$1,618,562 | |
| Original award | $1,620,596 |
Show all 21
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| University Of Texas Health Science Center At Houston | $59,732 | |
| ST Antony's College In The University Of Oxford | $254,630 | |
| ST Francis Hospital, Roslyn, New York | $214,959 | |
| ST Francis Hospital, Roslyn, New York | $465,688 | |
| Brigham & Womens Hospital Inc. | $495,246 | |
| New York University | $101,829 | |
| The Feinstein Institutes For Medical Research | $63,189 | |
| Albert Einstein College Of Medicine | $165,480 | |
| The Trustees Of Columbia University In The City Of New York | $102,060 | |
| Weill Medical College Of Cornell University | $461,792 |
Quick answers
Who received award R01HL159433?
R01HL159433 was awarded to Icahn School Of Medicine At Mount Sinai by National Heart Lung and Blood Institute (National Institutes of Health) on September 6, 2021.
How much is award R01HL159433 worth?
$9,939,877 has been obligated on R01HL159433.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award